keyword
MENU ▼
Read by QxMD icon Read
search

pbsc

keyword
https://www.readbyqxmd.com/read/30099684/dimethyl-sulfoxide-induced-tonic-clonic-seizure-and-cardiac-arrest-during-infusion-of-autologous-peripheral-blood-stem-cells
#1
Senem Maral, Murat Albayrak, Cigdem Pala, Abdulkerim Yildiz, Osman Sahin, Hacer Berna Ozturk
Various side effects associated with dimethyl sulfoxide (DMSO) which is used for cryopreservation of bone marrow or peripheral blood progenitor cells (PBPCs) have been reported. Among the central nervous system side effects the epileptic seizures, stroke, transient and temporary leucoencephalopathy, and global amnesia are well known. Herein we report a 52-year-old man who experienced tonic-clonic seizure within minutes after the initiation of DMSO cryopreserved autologous PBPC infusion. Unfortunately, he also developed cardiac arrest and required intubation for ventilation after the seizure...
August 11, 2018: Cell and Tissue Banking
https://www.readbyqxmd.com/read/30077015/reduced-intensity-conditioning-followed-by-related-and-unrelated-allografts-for-hematologic-malignancies-expanded-analysis-and-long-term-follow-up
#2
Erica Dahl Warlick, Todd E DeFor, Nelli Bejanyan, Shernan Holtan, Margaret MacMillan, Bruce R Blazar, Kathryn Dusenbery, Mukta Arora, Veronika Bachanova, Sarah Cooley, Aleksandr Lazaryan, Philip McGlave, Jeffrey S Miller, Armin Rashidi, Arne Slungaard, Gregory Vercellotti, Celalettin Ustun, Claudio Brunsein, Daniel Weisdorf
Reduced intensity conditioning (RIC) extends the curative potential of allogeneic hematopoietic cell transplantation (HCT) to patients with hematologic malignancies unable to withstand myeloablative conditioning. We prospectively analyzed the outcomes of 292 consecutive patients, median age of 58 (range 19-75), with hematologic malignancies treated with a uniform RIC regimen of cyclophosphamide, fludarabine, and total body irradiation (TBI) (200 cGy) with or without anti-thymocyte globulin (ATG) and cyclosporine and mycophenolate mofetil graft versus host disease prophylaxis followed by allogeneic HCT at the University of Minnesota from 2002-2016...
August 1, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/30032508/-efficiency-of-da-epoch-and-ma-chemotherapy-in-the-mobilization-of-autologous-peripheral-blood-stem-cells-in-non-hodgkin-s-lymphoma
#3
L S Liao, Z H Zheng, T N Wei, S Qu, Y Xie, Z H Wang, B Y Chen
Objective: To study the effect and safety of the DA-EPOCH chemotherapy combined with G-CSF and the MA chemotherapy combined with G-CSF on mobilizing and collecting the peripheral blood stem cells and the later hematopoietic recovery. Methods: A total of 40 patients accepted mobilization and collection of peripheral blood stem cells(PBSC) after being treated by DA-EPOCH+ G-CSF and MA+ G-CSF therapy respectively, and performed auto-transfusion. The effect of mobilization, the adverse effects and the hematopoietic recovery after autologous transplantation were analyzed retrospectively...
July 10, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/30026107/low-dose-atlg-as-prophylaxis-of-gvhd-in-unrelated-transplants-for-acute-leukemias-and-myelodisplastic-syndromes
#4
Francesca Bonifazi, Jacopo Olivieri, Mariarosaria Sessa, Elisa Dan, Barbara Sinigaglia, Simonetta Rizzi, Maria Rosa Motta, Andrea Bontadini, Francesca Ulbar, Valeria Giudice, Cristina Papayannidis, Antonio Curti, Angela Chiereghin, Tiziana Lazzarotto, Michele Cavo, Mario Arpinati
Chronic Graft Versus Host Disease (cGVHD) is a major complication after stem cell transplantation (HSCT). Several randomized studies already demonstrated that anti-T lymphoglobulin (ATLG) is effective in preventing GVHD after myeloablative unrelated and HLA-identical sibling transplants. However, the issue of the doses and the potential increase of relapses still remain unsolved. Here we report data on 190 patients with acute leukemia and myelodysplastic syndrome who underwent an unrelated HSCT with low ATLG dose (15-30 mg/kg) given at an earlier timing (-6 to-2)...
July 16, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/30009980/reduced-intensity-conditioning-and-dual-t-lymphocyte-suppression-with-anti-thymocyte-globulin-and-post-transplant-cyclophosphamide-as-graft-versus-host-disease-prophylaxis-in-haploidentical-stem-cell-transplants-for-hematological-malignancies
#5
Arjun Datt Law, Maria Queralt Salas, Wilson Lam, Fotios V Michelis, Santhosh Thyagu, Dennis Dong Hwan Kim, Jeffrey Howard Lipton, Rajat Kumar, Hans Messner, Auro Viswabandya
BACKGROUND: Haploidentical hematopoietic stem cell transplantation (haploSCT) with conditioning regimens using post-transplant cyclophosphamide (PTCy) for peripheral blood stem cell (PBSC) grafts is limited by comparably higher rates of acute and chronic graft-versus-host disease (GVHD). Anti-thymocyte globulin (ATG) may mitigate this risk. We evaluated haploSCT after reduced intensity conditioning (RIC) with ATG, PTCy & cyclosporine to prevent rejection and GVHD. METHODS: Fifty adults underwent haploSCT from August 2016-February 2018...
July 12, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29987350/haplo-identical-allografting-with-post-transplant-cyclophosphamide-in-high-risk-patients
#6
Lucia Brunello, Roberto Passera, Chiara Maria Dellacasa, Luisa Giaccone, Ernesta Audisio, Dario Ferrero, Stefano D'Ardia, Bernardino Allione, Semra Aydin, Moreno Festuccia, Giuseppe Lia, Elena Crisà, Enrico Maffini, Sara Butera, Alessandro Busca, Benedetto Bruno
Haplo-identical transplants (Haplo-Tx) are an important alternative for patients with hematological malignancies who lack a HLA-identical donor. Seventy-one T-replete Haplo-Tx were performed in 70 high-risk patients at our center; 22/70 (31%) patients with refractory/relapsed leukemia received sequential salvage therapy (SeqTh) with high-dose chemotherapy followed by Haplo-Tx during the chemotherapy-induced neutropenia. Graft-versus-host disease (GVHD) prophylaxis consisted of post-transplant cyclophosphamide (days + 3 and + 4) with tacrolimus and mycophenolic acid...
July 9, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29937455/gvhd-prevention-in-2018-tried-and-true-or-something-new
#7
Masumi Ueda
Graft-versus-host disease (GVHD) is a major contributor to early and late morbidity and mortality after allogeneic stem cell transplantation. Despite results from a randomized controlled trial demonstrating an increased risk of chronic GVHD with use of growth factor-mobilized peripheral blood stem cells (PBSC) compared with bone marrow, PBSCs are the most widely used graft source in allogeneic transplantation for hematologic neoplasms in the U.S. This lecture will review established, recent, and novel strategies for GVHD prevention in unrelated donor PBSC transplantation and will highlight ongoing clinical research at Fred Hutchinson Cancer Research Center...
2018: Keio Journal of Medicine
https://www.readbyqxmd.com/read/29937306/young-child-as-a-donor-of-cells-for-transplantation-and-lymphocyte-based-therapies
#8
REVIEW
Jan Styczynski
In most cases of hematopoietic cell transplantation (HSCT) in pediatric recipient, the priority is given to bone marrow as a hematopoietic cell (HSC) source. The same expectations should be given to pediatric sibling donor. Bone marrow (BM) harvest is a standard method of HSC collection in pediatric siblings, however peripheral blood HSC (PBSC) collection is safe in healthy pediatric donors, and target hematopoietic cell yields can be achieved. Bone marrow or peripheral blood cell collection, both hematopoietic cells and lymphocytes, in pediatric sibling donors is safe, however there is a small risk of severe adverse events (SAE); still the risk of SAE is lower in children than in adults...
June 2018: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29930241/t-cell-replete-haploidentical-peripheral-blood-hematopoietic-cell-transplantation-for-treatment-of-t-lymphoblastic-lymphoma
#9
Lixun Guan, Xiaohong Li, Huaping Wei, Zhenyang Gu, Shasha Zhao, Chengying Zhu, Nan Yang, Feiyan Wang, Lan Luo, Zhe Gao, Wenrong Huang, Honghua Li, Quanshun Wang, Daihong Liu, Xiaoxiong Wu, Chunji Gao
BACKGROUND There is currently little information on haploidentical hematopoietic cell transplantation (haplo-HCT) for T-lymphoblastic lymphoma (T-LBL). Data about peripheral blood stem cells (PBSC) as a reliable graft source for T-LBL treatment are lacking. MATERIAL AND METHODS T-LBL patients who underwent T cell-replete haploidentical peripheral blood hematopoietic cell transplantation (haplo-PBHCT) from July 2007 to January 2017 were retrospectively evaluated. RESULTS A total of 25 patients (age ≥15 years) with median age of 24 (range 15-51) years were enrolled...
June 22, 2018: Annals of Transplantation: Quarterly of the Polish Transplantation Society
https://www.readbyqxmd.com/read/29907809/killer-cell-immunoglobulin-like-receptor-ligand-mismatching-and-outcome-after-haploidentical-transplantation-with-post-transplant-cyclophosphamide
#10
Avichai Shimoni, Myriam Labopin, Francesca Lorentino, Maria Teresa Van Lint, Yener Koc, Zafer Gülbas, Johanna Tischer, Benedetto Bruno, Didier Blaise, Pietro Pioltelli, Boris Afanasyev, Fabio Ciceri, Mohamad Mohty, Arnon Nagler
Haploidentical stem cell transplantation with T cell-replete grafts and post-transplant cyclophosphamide (PTCy) is increasingly used with encouraging outcome. Natural killer (NK) cell alloreactivity, predicted by missing killer cell immunoglobulin-like receptor (KIR) ligands in the recipient that are present in their donor improves outcome of T cell-depleted haploidentical transplants. We explored the role of KIR ligand mismatching in 444 acute leukemia patients after T cell-replete transplants with PTCy. Thirty-seven percent of all patients had KIR ligand mismatching...
June 15, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/29906568/higher-cd45ra-regulatory-t-cells-in-the-graft-improves-outcome-in-younger-patients-undergoing-t-cell-replete-haploidentical-transplantation-where-donor-age-matters
#11
Sarita Rani Jaiswal, Prakash Bhakuni, Aby Joy, Nisha Murli, Ashok Rajoreya, Aditi Chakrabarti, Suparno Chakrabarti
To understand the phenomenon of early alloreactivity (EA) in younger children undergoing post-transplantation cyclophosphamide (PTCy)-based haploidentical transplantation, we studied the graft composition and the immune reconstitution in 32 consecutive patients (aged 2 to 25 years) undergoing PTCy and T cell costimulation blockade based peripheral blood stem cell transplantation with emphasis on CD45RA+ subset of regulatory T cells (Tregs). All but 1 engrafted, and 14 patients experienced EA (acute graft-versus-host disease grades II to IV, n = 8; and post-transplantation hemophagocytic syndrome, n = 6) with a cumulative incidence of 43...
June 13, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29795418/favorable-immune-recovery-and-low-rate-of-gvhd-in-children-transplanted-with-partially-t-cell-depleted-pbsc-grafts
#12
Christian Martin Seitz, Matthias Eyrich, Johann Greil, Patrick Schlegel, Tobias Feuchtinger, Peter Bader, Martin Ebinger, Carl Philipp Schwarze, Paul Gerhardt Schlegel, Michael Schumm, Rupert Handgretinger, Peter Lang
Transplantation of peripheral blood stem cells (PBSC) from matched unrelated donors (MUD) is still associated with a significant risk for graft vs. host disease (GvHD), especially in pediatric patients receiving grafts from adult donors containing high amounts of T cells. Here, we present long-term follow-up results on 25 pediatric patients, (acute leukemia n = 15, NHL n = 3, CML n = 3, MDS n = 5), transplanted with CD34 or CD133 positively selected PBSC from MUDs supplemented with an add-back of 1 × 107 /kg body weight (kgBW) unselected T cells resulting in a median T-cell depletion (TCD) of 1...
May 24, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29790808/comparison-of-time-to-engraftment-between-autologous-patients-receiving-washed-versus-non-washed-cryopreserved-peripheral-blood-stem-cell-products
#13
Ronit Reich-Slotky, Sarah S Makhani, Ljiljana V Vasovic, Roger N Pearse, Adriana Rossi, Adrianne Philips, Melissa M Cushing, Amrita D Singh, Koen van-Besien
Washing cryopreserved peripheral blood stem cell (PBSC) products can decrease infusion-related adverse reactions but can also result in cell loss and reduced cell viability. To assess the risk and benefit of washing products, we compared the time to neutrophil and platelet engraftment between autologous patients that received washed products (n = 201) and non-washed products (n = 89). The effect of the other variables, including age, gender, diagnosis, transplant dose, method of stem cell mobilization, and growth factor support regimen post-transplant, was assessed...
May 23, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29773496/reflections-on-methodical-approaches-to-hematopoietic-stem-cell-collection-in-children
#14
REVIEW
Claudia Del Fante, Jerard Seghatchian, Cesare Perotti
Pediatric peripheral blood stem cell collection (PBSC) is challenging because it has potentially more side effects than in adults due to the small body mass and unique physiology of children. The extracorporeal volume of the cell separator device, poor venous access and metabolic complications due to citrate toxicity are the main problems to face during PBSC collection. These aspects are more relevant in very low body weight (BW) children of 20 kg or lower. An efficient, experienced and well-prepared team of pediatricians, apheresis physicians and nurses, and physicians involved in CVC positioning is crucial to performing a safe PBSC collection...
June 2018: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29764770/haploidentical-stem-cell-transplantation-bone-marrow-vs-peripheral-blood
#15
REVIEW
Zafer Gulbas
Hematopoietic stem cells may be obtained by collection of bone marrow, mobilization and collection of peripheral blood stem cells or umbilical cord blood. Transplantation of peripheral blood hematopoietic cells has increased due to faster engraftment and practicability in both the related, unrelated or haploidentical setting. We reviewed the question of which stem cell source - bone marrow (BM) or peripheral blood (PBSC) - is the most suitable for individuals undergoing haploidentical stem cell transplantation...
April 2018: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29726078/unrelated-and-related-donor-transplantation-for-beta-thalassemia-major-a-single-center-experience-from-india
#16
M Joseph John, Amrith Mathew, Chepsy C Philip, Sohan Singh, Tanuja Tanuja, Naveen Kakkar
Hematopoietic stem cell transplantation (HSCT) remains the only curative treatment in patients with β-thalassemia major. A matched sibling or a related donor is usually found in only 25%-30% of the patients. There are limited data on matched unrelated donor (MUD) transplants from India. We reviewed HSCT outcome in 56 children with TM who underwent 57 transplants at our center. Related donor (RD) (n=43) and MUD (n=14) transplants were performed with TreoFluT-based conditioning regimen in majority (95%) of patients...
August 2018: Pediatric Transplantation
https://www.readbyqxmd.com/read/29703966/cd3-graft-cell-count-influence-on-chronic-gvhd-in-haploidentical-allogeneic-transplantation-using-post-transplant-cyclophosphamide
#17
A Mussetti, C De Philippis, C Carniti, M Bastos-Oreiro, J Gayoso, N Cieri, M Pennisi, F Ciceri, R Greco, J Peccatori, F Patriarca, J Mariotti, L Castagna, P Corradini
The effects of graft or donor characteristics in haploidentical hematopoietic cell transplantation (HCT) using post-transplant cyclophosphamide (PT-Cy) are largely unknown. In this multicenter retrospective study we analyzed the correlations between graft cell composition (CD34+, CD3+) and donor features on transplant outcomes in 234 patients who underwent HCT between 2010 and 2016. On multivariate analysis, the use of peripheral blood stem cells (PBSC) was associated with an increased incidence of grade 2-4 acute GVHD [HR 1...
April 27, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29662864/expression-of-adhesion-molecules-on-cd34-cells-from-steady-state-bone-marrow-before-and-after-mobilization-and-their-association-with-the-yield-of-cd34-cells
#18
Karin Zattar Cecyn, Eliza Y S Kimura, Dulce Marta S M Lima, Miyoko Yamamoto, José Orlando Bordin, José Salvador R de Oliveira
Background: Cell adhesion molecules (CAMs) expressed on hematopoietic progenitor cells (HPCs), endothelial cells, and stromal cells play a pivotal role in the mobilization of CD34+ cells. Herein, we conducted a non-randomized peripheral blood stem cell (PBSC) mobilization study aimed to compare the potential differences in the expressions of several CAMs and chemokines on CD34+ cells obtained from bone marrow aspirate before and after HPC mobilization from patients with hematologic malignancies and healthy donors...
March 2018: Blood Research
https://www.readbyqxmd.com/read/29656139/analysis-of-clinical-factors-and-outcomes-associated-with-nonuse-of-collected-peripheral-blood-stem-cells-for-autologous-stem-cell-transplants-in-transplant-eligible-patients-with-multiple-myeloma
#19
Ankit Kansagra, Wilson I Gonsalves, Morie A Gertz, Francis K Buadi, David Dingli, Angela Dispenzieri, Martha Q Lacy, Suzanne R Hayman, Prashant Kapoor, Eli Muchtar, Taxiarchis V Kourelis, Rahma Warsame, Nelson Leung, Steven R Zeldenrust, John A Lust, S Vincent Rajkumar, Robert A Kyle, William Hogan, Shaji K Kumar
Collection and storage of peripheral blood stem cells (PBSCs) for use in autologous stem cell transplantation (ASCT) upon first disease relapse is an accepted practice for eligible patients with multiple myeloma (MM). However, little is known about the factors and outcomes associated with nonuse of these collected and stored PBSCs by MM patients who intended to have a delayed ASCT. From January 1, 2004 to December 31, 2014 we identified 342 patients who underwent collection and storage of their PBSCs in anticipation of a delayed ASCT upon first disease relapse...
April 12, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29656137/haploidentical-peripheral-blood-stem-cell-transplantation-demonstrates-stable-engraftment-in-adults-with-sickle-cell-disease
#20
Santosh L Saraf, Annie L Oh, Pritesh R Patel, Karen Sweiss, Matthew Koshy, Sally Campbell-Lee, Michel Gowhari, Shivi Jain, David Peace, John G Quigley, Irum Khan, Robert E Molokie, Nadim Mahmud, Victor R Gordeuk, Damiano Rondelli
We report on the screening and development of haploidentical hematopoietic stem cell transplantation (HSCT) for adult patients with clinically aggressive sickle cell disease (SCD) at our institution. Of 50 adult SCD patients referred for HSCT between January 2014 and March 2017, 20% were denied by insurance. Of 41 patients initially screened, 10% lacked an available haploidentical donor, 29% had elevated donor-specific antibodies (DSAs), and 34% declined to proceed to HSCT. All 10 patients who were transplanted received peripheral blood stem cells...
April 12, 2018: Biology of Blood and Marrow Transplantation
keyword
keyword
161800
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"